Amsterdam wins vote to become new home of European Medicines Agency

21 November 2017

European heads of state have chosen Amsterdam, Netherlands, as the new home for the European Medicines Agency post- Brexit, simultaneously ending months of speculation and the hopes of 18 other nations bidding to host the prestigious organization.

In a nail-biting finale, Italy narrowly lost out after leading the first round of voting, with Copenhagen and Amsterdam close behind.

The decision, which was welcomed by EMA boss Guido Rasi, will mitigate concerns over disruption due to staff loses. As well as being scored highly by current EMA staff, Amsterdam was judged by the agency to be a highly suitable candidate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK